WARNING:
JavaScript is turned OFF. None of the links on this concept map will
work until it is reactivated.
If you need help turning JavaScript On, click here.
This Concept Map, created with IHMC CmapTools, has information related to: LC efficacy endpoints 20150327, Non-target lesion evaluated by Qualitative Assessment, Repeated concepts/instances throughout the CMAP are denoted by dotted outline, Tumor Response is assessed with -Ultrasound -MRI -CT -PET/CT -Bone scan -Chest X-ray (CXR), Progression free survival (PFS) measured between Time periods, Existing lesion identified by Organ specific lesion ID, - PD associated with Date of tumor progression, Sum of longest diameters (SLD) have response options -Complete Response (CR) -Partial Response (PR) -Not all evaluated -Stable disease (SD) -Progressive disease (PD) -Any, OVERALL RESPONSE have response options -SD -PD -NE (inevaluable), LUNG CANCER EFFICACY ENDPOINTS include Disease free survival (DFS), newly added concepts are denoted by green color outlines, Anatomical region instantiated by -Lung -CNS (brain, leptomeninges) -Bone -Liver -Adrenal (L, R) -Mediastinum (anterior, middle, posterior) -Hilar (L, R) -Plural Fluid, Organ specific lesion ID includes -Lung -CNS (brain, leptomeninges) -Bone -Liver -Adrenal (L, R) -Mediastinum (anterior, middle, posterior) -Hilar (L, R) -Plural Fluid, Quantitative assessment represented by Sum of longest diameters (SLD), Overall Survival (OS) measured by Date of death of any cause, -Complete Response (CR) -Partial Response (PR) -Not all evaluated -Stable disease (SD) -Progressive disease (PD) -Any summarized into OVERALL RESPONSE, OVERALL RESPONSE have response options - CR - PR, Non-measurable lesions has subtype Non-target lesion, OVERALL RESPONSE derived from Sponsor specified Response Criteria (e.g. RECIST), Questions to the Division's SMEs are denoted by red color text or shapes, Time to progression of cancer symptoms includes -cough -shortness of breath -chest pain -fatigue -other